These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24850536)

  • 21. Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets.
    Cox RJ; Major D; Pedersen G; Pathirana RD; Hoschler K; Guilfoyle K; Roseby S; Bredholt G; Assmus J; Breakwell L; Campitelli L; Sjursen H
    PLoS One; 2015; 10(7):e0131652. PubMed ID: 26147369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.
    Liu F; Sun X; Fairman J; Lewis DB; Katz JM; Levine M; Tumpey TM; Lu X
    Virology; 2016 May; 492():197-203. PubMed ID: 26967975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.
    Gillard P; Giet D; Heijmans S; Dramé M; Walravens K; Roman F
    Trials; 2014 Oct; 15():419. PubMed ID: 25354581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models.
    Song MS; Moon HJ; Kwon HI; Pascua PN; Lee JH; Baek YH; Woo GJ; Choi J; Lee S; Yoo H; Oh I; Yoon Y; Rho JB; Sung MH; Hong SP; Kim CJ; Choi YK
    J Microbiol; 2012 Jun; 50(3):478-88. PubMed ID: 22752912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.
    Rockman S; Brown LE; Barr IG; Gilbertson B; Lowther S; Kachurin A; Kachurina O; Klippel J; Bodle J; Pearse M; Middleton D
    J Virol; 2013 Mar; 87(6):3053-61. PubMed ID: 23283953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus.
    Park SJ; Si YJ; Kim J; Song MS; Kim SM; Kim EH; Kwon HI; Kim YI; Lee OJ; Shin OS; Kim CJ; Shin EC; Choi YK
    Virology; 2016 Nov; 498():36-43. PubMed ID: 27543757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal immunization of recombinant Lactococcus lactis induces protection against H5N1 virus in ferrets.
    Lei H; Peng X; Ouyang J; Zhao D; Jiao H; Shu H; Ge X
    Virus Res; 2015 Jan; 196():56-9. PubMed ID: 25445345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization.
    Middleton D; Rockman S; Pearse M; Barr I; Lowther S; Klippel J; Ryan D; Brown L
    J Virol; 2009 Aug; 83(15):7770-8. PubMed ID: 19457991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.
    Perrone LA; Ahmad A; Veguilla V; Lu X; Smith G; Katz JM; Pushko P; Tumpey TM
    J Virol; 2009 Jun; 83(11):5726-34. PubMed ID: 19321609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
    Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF
    Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.
    Yang P; Duan Y; Zhang P; Li Z; Wang C; Dong M; Tang C; Xing L; Gu H; Zhao Z; Liu X; Zhang S; Wang X
    PLoS One; 2012; 7(1):e30252. PubMed ID: 22279575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
    Chada KE; Forshee R; Golding H; Anderson S; Yang H
    Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.
    Khurana S; Verma S; Verma N; Crevar CJ; Carter DM; Manischewitz J; King LR; Ross TM; Golding H
    J Virol; 2011 Feb; 85(3):1246-56. PubMed ID: 21084473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With
    Zhou F; Hansen L; Pedersen G; Grødeland G; Cox R
    Front Immunol; 2021; 12():747774. PubMed ID: 34887855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.